Nothing Special   »   [go: up one dir, main page]

Kuroda et al., 1987 - Google Patents

Incidence of antibody to HTLV‐I is not increased in Japanese MS patients

Kuroda et al., 1987

Document ID
3024062346936466450
Author
Kuroda Y
Shibasaki H
Sato H
Okochi K
Publication year
Publication venue
Neurology

External Links

Snippet

To examine the association between MS and anti-human T-cell lymphotropic virus-I (HTLV-I) antibody, we studied serum and CSF antibody to HTLV-I in 27 Japanese MS patients by an indirect immunofluorescence method sensitive and specific enough to detect carriers of …
Continue reading at www.neurology.org (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Similar Documents

Publication Publication Date Title
Brun-Vezinet et al. Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS
Joag et al. Identification of preferential CD4+ T-cell targets for HIV infection in the cervix
Jacobson et al. Immunological findings in neurological diseases associated with antibodies to HTLV‐I: activated lymphocytes in tropical spastic paraparesis
Mochizuki et al. Uveitis associated with human T-cell lymphotropic virus type I
Levin et al. HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system
US6534259B1 (en) Regressive behavioral disorder diagnosis
Webster et al. Isolation of retroviruses from two patients with" common variable" hypogammaglobulinaemia
Afrasiabi et al. Characterization of a distinct subgroup of high-risk persons with Kaposi's sarcoma and good prognosis who present with normal T4 cell number and T4: T8 ratio and negative HTLV-III/LAV serologic test results
Yoshimura et al. Clinical and immunologic features of human T-cell lymphotropic virus type I uveitis
ROGERS et al. Advances and problems in the diagnosis of human immunodeficiency virus infection in infants
Dorosko et al. Primary human mammary epithelial cells endocytose HIV-1 and facilitate viral infection of CD4+ T lymphocytes
US5529765A (en) Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids
Kuroda et al. Incidence of antibody to HTLV‐I is not increased in Japanese MS patients
Matsuzaki et al. Monoclonal gammopathies in adult T‐cell leukemia
McSharry et al. Detection and quantitation of human immunodeficiency virus-infected peripheral blood mononuclear cells by flow cytometry
Sidi et al. Adult T‐cell lymphoma in Israeli patients of Iranian origin
Sherman et al. Identification of human T cell leukemia/lymphoma virus type I antibodies, DNA, and protein in patients with polymyositis
Kreiss et al. Human T cell leukemia virus type III antibody, lymphadenopathy, and acquired immune deficiency syndrome in hemophiliac subjects. Results of a prospective study
Takahashi et al. Cutaneous-type adult T-cell leukemia/lymphoma: a unique clinical feature with monoclonal T-cell proliferation detected by Southern blot analysis
Achiron et al. Spastic paraparesis associated with human T‐lymphotropic virus type I: A clinical, serological, and genomic study in Iranian‐born Mashhadi Jews
McKendall et al. HTLV‐I‐associated myelopathy endemic in Texas‐born residents and isolation of virus from CSF cells
Levin et al. Spontaneous human mononuclear cell cytotoxicity to cultured tumor cells: reproducibility of serial measurements with the use of a chromium-51-release microcytotoxicity assay
Skinhøj Hepatitis-associated antigen, subtypes d and y: An epidemiological and clinical evaluation
Catalan-Soares et al. HTLV-2 horizontal and vertical transmission in a family from a Brazilian urban area: seroepidemiological, clinical and molecular study
Lefrére et al. Follow-up of subjects with isolated and persistent anti-core (anti-p24 or anti-p17) antibodies to HIV